IBIO
CREATIVE WAYSAccording to source, Pinterest has recently seen the highest searches ever around mental wellness ideas including meditation (+44%), gratitude (+60%) and positivity (+42%) that jumped from February to May. Pinners are looking for creative ways to navigate and cope with their “new normal,” so they took a closer look at their shifting priorities to understand which trends would live out the remainder of 2020.
Lovely simple trade here from IbioWe have standard bounce off of Fib (61.8%)
Waited for a break out of the vertical res
added on the BO, will hold to 7 depending on what happens AH tonight
iBio Chart UpdateAnother one of these "COVID Stocks" - Decisions, decisions upcoming - take it or leave it at this point.
Don't take as financial advice...
VBIV day trade [Price Target: $1.60]IFFFFF the $1.98 - $2.00 support line holds and buying pressure increases, I expect to see a pretty big upward price movement for the day. Remember folks, just ideas!
IBIO Future Projection Analysis *Future Spike CONFIRMED!*AMEX:IBIO IBIO spike confirmed after hours. May appear as gap up in morning. On COVID-19 news. Check it out.
IBIO Future Projection Analysis *Future Spike UPDATE and REVISEDIBIO There was a big spike of a corona virus issue, but pipeline is Good. Still Bullish. I expect at least $1.60.
IBIO Future Projection Analysis *Future Spike UPDATE*AMEX:IBIO Bollinger bands are compressing, indicating a future breakout/breakdown. I expect a move to $1.18+; however, if sustained market pressure persists, it may be flipped into a breakdown. But I'm still bullish.
IBIO Future Projection Analysis *Future Spike/Breakout Detected*AMEX:IBIO Time will tell if this is correct.
$COCP Short Articles Published Drowned out by FACTS PPS Rises03-06-2020, 3.5 Million Share Institutional Buy-In tells only a snippet of the overall story with this dream stock.
sec.report
To get the real grasp of what we have here, look to my previous post and take in this analogy as deeply as possible:
In the Coronavirus Market: $COCP is to Treatment what $IBIO is to Vaccines or what $OPK is to Testing.
$COCP has completed all the financing and funding needed with two public offerings recently and are now aggressively pursing the development of Novel Anitiviral Compounds for treatment of any Corona infections including COVID-19
They have exclusive patent rights to the treatment and are in the process of advancing it quickly through a preclinical trial program.
Shorts will continue to write articles to downplay these facts as much as possible because the stock has a HUGE short position
$COCP Clears the Runway for a $10+ move In the coming daysBOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage
Biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program.
finance.yahoo.com
“Following our acquisition of patent rights and know-how from KSURF
and our recently completed financing,
we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform.
Given the global threat of COVID1-9, our primary goal is to advance
our Coronavirus program into preclinical development.
We will seek opportunities for collaborations as we advance our programs,” stated
Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.
Cocrystal recently entered into a license agreement with KSURF
to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections.
Cocrystal intends to pursue research and development of theses
antiviral compounds, including preclinical and clinical development.
This license advances the Company's antiviral programs significantly by providing potent compounds for further development.
For additional information about the Company’s development pipeline, please visit www.cocrystalpharma.com.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections.
Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development.
“We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.”
Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
